Chinese Patent Medicine Market Trends Analysis and 2018 Forecasts

DALLAS, October 24, 2014 /PRNewswire/ --

ReportsnReports.com adds Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report to the pharmaceuticals category of its online industry research reports library. It analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine industry in China. Complete report is available at http://www.reportsnreports.com/reports/311971-research-and-development-trend-forecast-of-chinese-patent-medicine-in-china-2014-2018.html .

According to Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report, the implementation of New Medical Reform Plan provides solid guarantee for the development of Chinese patent medicine, but also National Essential Drugs List lists large batch of Chinese Patent Medicine, which drives the continual expansion of Chinese patent medicine market scale in China effectively. In 2009, the cumulative output of Chinese patent medicine was 1.8037 million ton, since 2010, the Chinese patent medicine industry has been maintaining fast growth, the cumulative output was 1.9977 million ton in 2010 and 3.1052 million ton in 2013.

With the era development, the health concept has been given new connotation, the third state (Sub-health state) and its harm has cause people's extensive concerns; and with the improvement of living standard, people long for life quality and long life increasingly. Human medical model has been transformed from the pure "biomedical model" to the "biological-psychology-sociological model", and from treatment of disease to the model combining prevention, health, treatment and recovery.

The chemical drugs bite off more than they can chew in this field, while the profound Chinese patent medicine are causing people's attention and playing important role in health increasingly, and the rush of health cult provides valuable opportunities and extensive space for Chinese patent medicine development in China.

Companies like Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd, Jilin Xiuzheng Pharmaceutical Group, Yangtze River Pharmaceutical Group, Chongqing Taiji Industry (Group) Co., Ltd and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd are profiled in this research available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=311971 .

Table of Contents for Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report covers:

1. Overview of Chinese Patent Medicine
1.1 Concept
1.2 Product Classification

2. Development Environment of Chinese Patent Medicine in China
2.1 Economic Development Environment in China
2.2 Related Industrial Policies, Law, Regulations and Standards
2.2.1 Influence on Chinese Patent Medicine by New Medical Reform Policy
2.2.2 Chinese Patent Medicine Development in "the 12th Five Years Plan" Period
2.2.3 Policy Summary of Medicine Industry in China
2.2.4 Related Industrial Standards
2.3 Many Countries with Restriction on Sales of Chinese Patent Medicine

3. Current Status of Chinese Patent Medicine Industry in China
3.1 Development History
3.2 Current Status of Overall Development
3.2.1 Current Status of Chinese Patent Medicine Development in China
3.2.2 Current Status of Chinese Patent Medicine Trade in China
3.3 Competition Pattern in Chinese Patent Medicine Industry

4. Analysis and Forecast on Chinese Patent Medicine Market Scale in China
4.1 Output
4.1.1 Output Analysis
4.1.2 Output Forecast
4.2 Sales
4.2.1 Sales Analysis
4.2.2 Sales Structure in 2013
4.2.3 Sales Forecast
4.3 Market Segmentation
4.3.1 Cardio-cerebrovascular Diseases
4.3.2 Tumor diseases
4.3.3 Respiratory Diseases
4.3.4 Bone Diseases

5. Analysis on Import and Export of Chinese Patent Medicine in China
5.1 Import Volume and Value in 2011- the First Half Year of 2014
5.2 Export Volume and Value in 2011- the First Half Year of 2014
5.3 Main Import Sources and Export Destinations by Trade Value in the First Half Year of 2014

6. Main Chinese Patent Medicine Enterprises in China
6.1 Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd
6.1.1 Company Profile
6.1.2 Competitiveness
6.1.3 Business Performance
6.1.4 Development Strategy
6.1.5 Main Business and Products
6.2 Jilin Xiuzheng Pharmaceutical Group
6.2.1 Company Profile
6.2.2 Competitiveness
6.2.3 Business Performance
6.2.4 Main Products
6.3 Yangtze River Pharmaceutical Group
6.3.1 Company Profile
6.3.2 Competitiveness
6.3.3 Business Performance
6.3.4 Development Strategy
6.3.5 Main Products
6.4 Chongqing Taiji Industry (Group) Co., Ltd
6.4.1 Company Profile
6.4.2 Competitiveness
6.4.3 Business Performance
6.4.4 Development Strategy
6.4.5 Main Products
6.5 China Resources Sanjiu Medical & Pharmaceutical Co., Ltd
6.5.1 Company Profile
6.5.2 Competitiveness
6.5.3 Business Performance
6.5.4 Development Strategy
6.5.5 Main Business and Products

7. Future Development Trend of Chinese Patent Medicine in China 

8. Expert Suggestion on investment in Chinese Patent Medicine Industry
8.1 SWOT Analysis
8.2 Market Strategy Analysis

Another research titled China Chinese Patent Medicine Industry Report, 2013-2016 says that in the international market, there is a higher recognition of Chinese patent medicine in Asia, especially in Southeast Asia, and many varieties of Chinese patent medicine are included in the Medicare drug list stipulated by Southeast Asian countries, and special departments are established for management research as well. But in the U.S. and European markets, affected by access restrictions and differences in medical health concept, Chinese patent medicine is still only sold as health care product. However, the international market sees strong demand for plant extracts (mostly traditional Chinese medicinal materials) whose export value in 2010-2013 grew at a CAGR of 44% and accounted for approximately 50% of China's TCM export value. Companies like Tianjin Tasly Pharmaceutical Co., Ltd., Guizhou Yibai Pharmaceutical Co., Ltd., Yunnan Baiyao Group Co., Ltd., Zhangzhou Pientzehuang Pharmaceutical Co., Ltd., Shandong Dong-E E-Jiao Co., Ltd., China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu), Shanghai Kaibao Pharmaceutical Co., Ltd., Kangmei Pharmaceutical Co., Ltd., Tibet Rhodiola Pharmaceutical Holding Co., Ltd. and Beijing Tongrentang Co., Ltd. (TRT) are profiled in this research available for purchase at http://www.reportsnreports.com/Purchase.aspx?name=276598 .

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:  

Ritesh Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel:  +1-888-391-5441
sales@reportsandreports.com  

Connect With Us on:  

Facebook:  https: //www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn:  www.linkedin.com/company/reportsnreports

Twitter:  https: //twitter.com/marketsreports

Pinterest:  www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds:  http: //www.reportsnreports.com/feed/l-latestreports.xml